Associate Professor, Internal Medicine, Washington University School of Medicine
Oncology
Dr. Gerald P. Linette, MD
|
|
Give Review
Gerald Linette works in the field of Oncology. He researched medicine at Georgetown University School of Medicine. Georgetown University School of Medicine has a rank of 49 in research and a 84 in primary care He received awards:"CMS Meaningful Use Stage 1 Certification". Gerald Linette is a published physician as well. He has 69 publications published. The latest was: Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Dr. Gerald P. Linette accepts Medicare.
Publications
- Extensive tumoral melanosis associated with ipilimumab-treated Melanoma.
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral Melanoma.
- Effect of selumetinib vs chemotherapy on progression-free survival in uveal Melanoma: a randomized clinical trial.
- Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of Melanoma.
- Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendroGliomas and mixed oligoastrocytomas.
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T Cells in myeloma and melanoma.
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma.
- Neoadjuvant treatment of a solitary melanoma Brain metastasis with vemurafenib.
- Clonal architectures and driver mutations in metastatic Melanomas.
- A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
- Production of a fibroblast-stimulating factor by Schistosoma mansoni antigen-reactive T Cell clones.
- InDuction of anti-HIV neutralizing antibodies by synthetic peptides.
- In vitro granuloma formation using defined antigenic nidi.
- HIV-1-infected T Cells show a selective signaling defect after perturbation of CD3/antigen receptor.
- The immune response to Schistosoma mansoni infections in inbred rats. VI. Regulation by T Cell subpopulations.
- In vivo T Cell depletion regulates resistance and morbidity in murine schistosomiasis.
- HLA-A2.1/K(b) transgenic murine dendritic Cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-p...
- Adjuvant high-dose interferon alfa-2b in patients with high-risk Melanoma.
- In vitro priming with adenovirus/gp100 antigen-transduced dendritic Cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T Cells in patients with melanoma.
- Cross talk between Cell death and Cell cycle progression: BCL-2 regulates NFAT-mediated activation.
- Potential clinical applications of signal transDuction measurements in marrow transplantation and HIV-1 infection.
- Bcl-2 is upregulated at the CD4+ CD8+ stage during positive selection and promotes thymocyte differentiation at several control points.
- Differentiation and Cell death: lessons from the immune system.
- Bcl-XL and Bcl-2 repress a common pathway of Cell death.
- Peripheral T-Cell lymphoma in lckpr-bcl-2 transgenic mice.
- Unimpaired thymic and peripheral T Cell death in mice lacking the nuclear receptor NGFI-B (Nur77).
- Reactive oxygen species and the regulation of Cell death by the Bcl-2 gene family.
- Bcl-2 gene family and the regulation of programmed Cell death.
- Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips.
- Molecular diagnostics in Melanoma.
- Ipilimumab monotherapy in patients with pretreated advanced Melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
- The regulation of resistance to Schistosoma mansoni by auto-anti-idiotypic immunity.
- Allogeneic substitution for nominal antigen-specific T-Cell clone reactivity in schistosomiasis.
- The regulation of resistance to Schistosoma mansoni by auto-anti-idiotypic immunity. II. Global qualitative and quantitative regulation.
- Resistance in murine schistosomiasis is contingent on activated IL-2 receptor-bearing L3T4+ lymphocytes, negatively regulated by Lyt-2+ Cells, and uninfluenced by the ...
- The regulation of resistance to Schistosoma mansoni by auto-anti-idiotypic immunity. III. An Analysis of effects on epitopic recognition, idiotypic expression, and ant...
- Ras-associated protein-1 regulates extraCellular signal-regulated kinase activation and migration in melanoma Cells: two processes important to melanoma tumorigenesis ...
- A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic Malignant melanoma: a phase 2 consortium study.
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced...
- OligodendroGliomas in children.
- Central nervous system Cancers.
- Improved survival with ipilimumab in patients with metastatic Melanoma.
- Immunization using autologous dendritic Cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
- Immunodeficient mouse strains display marked variability in growth of human melanoma Lung metastases.
- Hepatic metastasis from uveal Melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization.
- CD40 regulates human dendritic Cell-derived IL-7 production that, in turn, contributes to CD8(+) T-Cell antigen-specific expansion.
- Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced Melanoma: a report from the 11715 Study Group.
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
- Human major histocompatibility complex (MHC) class I molecules with disulfide traps secure Disease-related antigenic peptides and exclude competitor peptides.
- Hepatic arterial chemoembolization for management of metastatic Melanoma.
- Melanocyte receptors: clinical implications and therapeutic relevance.
- Gene expression profiles predict early relapse in ovarian Cancer after platinum-paclitaxel chemotherapy.
- Biomarkers in melanoma: stage III and IV Disease.
- Targeted therapies for Cancer 2004.
- Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging.
- DNA ploidy and cell cycle analysis in breast Cancer.
- HER-2/neu testing in breast Cancer.
- Pharmacogenomics.
- Breast Cancer biomarkers and molecular medicine: part II.
- Targeted therapy in breast Cancer: the HER-2/neu gene and protein.
- Breast Cancer biomarkers and molecular medicine.
- The Her-2/neu gene and protein in breast Cancer 2003: biomarker and target of therapy.
- Biomarkers in Melanoma: staging, prognosis and detection of early metastases.
- Biomarkers in Melanoma: predisposition, screening and diagnosis.
- Antimelanoma activity of CTL generated from peripheral blood mononuclear Cells after stimulation with autologous dendritic Cells pulsed with melanoma gp100 peptide G20...
- Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic Cell vaccine for metastatic melanoma.
- Disinfection of Goldmann tonometers against human immunodeficiency virus type 1.
- Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.
Schools
Georgetown University
Barnes Jewish Hospital
Massachusetts General Hospital
Washington University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Massachusetts General Hospital -
Washington University - Barnes-Jewish Hospital -
Georgetown University School of Medicine
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1114943420 | |
| NPPES Provider LastName | LINETTE | |
| NPPES Provider FirstName | GERALD | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 322.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 60.0 | |
| Percent Opioid Claims | 18.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114943420 |
| Last Name Of The Provider | LINETTE |
| First Name Of The Provider | GERALD |
| View All |
Similar Doctors
|
|
Dr. Antonella L. Rastelli, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Van Tine, MD |
|
|
Dr. Douglas R. Adkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bethany G. Sleckman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vorachart Auethavekiat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lukas D. Wartman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John F. Dipersio, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Rama Suresh, MD
This Doctor is OpenDoctor Recommended.
|